Ocular Therapeutix (OCUL) Current Leases (2019 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Current Leases of $3.1 million for Q2 2026, up 18.93% year-over-year from $2.6 million in Q2 2025, and down 1.51% on a QoQ basis from $3.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Current Leases (2019 - 2026) Analysis & Trends
Ocular Therapeutix has reported Current Leases for 8 years, with the latest figure at $3.1 million in Q2 2026.
- Current Leases for Q2 2026 came in at $3.1 million, up 18.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.1 million (up 18.93% YoY), and the FY2025 annual result was $2.8 million, up 45.73% from the prior year.
- Current Leases retreated to $3.1 million in Q2 2026, from $3.2 million in the prior quarter.
- Over five years, Current Leases peaked at $3.2 million in Q1 2026 and troughed at $1.5 million in Q1 2024.
- A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Current Leases.
- The widest annual swing landed in 2024, when Current Leases decreased 15.18%; it then soared 60.86% in 2025.
- A 5-year view of Current Leases shows it stood at $1.6 million in 2022, then decreased by 0.81% to $1.6 million in 2023, then increased by 21.88% to $1.9 million in 2024, then surged by 45.73% to $2.8 million in 2025, then increased by 10.83% to $3.1 million in 2026.
- Per Business Quant data, the three most recent Current Leases figures were $3.1 million in Q2 2026, $3.2 million in Q1 2026, and $2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.12 Mn |
| Mar 31, 2026 | 3.17 Mn |
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 2.16 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | 1.71 Mn |
| Mar 31, 2023 | 1.82 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.74 Mn |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 1.55 Mn |